Literature DB >> 16801444

Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.

Marc Wirden1, Bénédicte Roquebert, Anne Derache, Anne Simon, Claudine Duvivier, Jade Ghosn, Stephanie Dominguez, Véronique Boutonnet, Zaina Ait-Arkoub, Christine Katlama, Vincent Calvez, Anne-Genevieve Marcelin.   

Abstract

We analyzed 3,475 human immunodeficiency virus sequences and 241 therapeutic histories. The L74I mutation was carried by 7% of viruses. L74I was strongly associated with T215F, K70R, and V75M/S/T/A mutations and increased with the number of thymidine analog mutations. It seemed to be linked to the use of abacavir or efavirenz.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16801444      PMCID： PMC1489786          DOI： 10.1128/AAC.00092-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.

Authors:  Anne-Geneviève Marcelin; Constance Delaugerre; Marc Wirden; Pedro Viegas; Anne Simon; Christine Katlama; Vincent Calvez
Journal:  J Med Virol       Date:  2004-01       Impact factor: 2.327

2.  Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.

Authors:  T Imamichi; M A Murphy; H Imamichi; H C Lane
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

4.  Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group.

Authors:  P R Harrigan; C Stone; P Griffin; I Nájera; S Bloor; S Kemp; M Tisdale; B Larder
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

5.  Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Fernando A Frankel; Bruno Marchand; Dan Turner; Matthias Götte; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis.

Authors:  Ermioni T Panidou; Thomas A Trikalinos; John P A Ioannidis
Journal:  AIDS       Date:  2004-11-05       Impact factor: 4.177

7.  Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.

Authors:  Adrian S Ray; Aravind Basavapathruni; Karen S Anderson
Journal:  J Biol Chem       Date:  2002-08-09       Impact factor: 5.157

8.  Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity.

Authors:  Karidia Diallo; Bruno Marchand; Xin Wei; Luciano Cellai; Matthias Götte; Mark A Wainberg
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.

Authors:  J P Kleim; M Rösner; I Winkler; A Paessens; R Kirsch; Y Hsiou; E Arnold; G Riess
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

Authors:  M J Kozal; K Kroodsma; M A Winters; R W Shafer; B Efron; D A Katzenstein; T C Merigan
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391
View more
  3 in total

Review 1.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

2.  HIV Reverse Transcriptase and Protease Genes Variability Can Be a Biomarker Associated with HIV and Hepatitis B or C Coinfection.

Authors:  Natália Mirele Cantão; Lauana Fogaça de Almeida; Ivan Rodrigo Wolf; Rodrigo Oliveira Almeida; Andressa Alves de Almeida Cruz; Caroline Nunes; Alexandre Naime Barbosa; Guilherme Targino Valente; Maria Inês de Moura Campos Pardini; Rejane Maria Tommasini Grotto
Journal:  Sci Rep       Date:  2018-05-29       Impact factor: 4.379

3.  Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.

Authors:  J Gregson; S Y Rhee; R Datir; D Pillay; C F Perno; A Derache; R S Shafer; R K Gupta
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.